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Magnetic nanotherapeutics for
dysregulated synaptic plasticity
during neuroAIDS and drug abuse
Vidya Sagar†, Venkata Subba Rao Atluri†, Sudheesh Pilakka-Kanthikeel and Madhavan Nair*
Abstract
The human immunodeficiency virus (HIV) is a neurotropic virus. It induces neurotoxicity and subsequent brain
pathologies in different brain cells. Addiction to recreational drugs remarkably affects the initiation of HIV infections
and expedites the progression of acquired immunodeficiency syndrome (AIDS) associated neuropathogenesis.
Symptoms of HIV-associated neurocognitive disorders (HAND) are noticed in many AIDS patients. At least 50 % of
HIV diagnosed cases show one or other kind of neuropathological signs or symptoms during different stages of
disease progression. In the same line, mild to severe neurological alterations are seen in at least 80 % autopsies of
AIDS patients. Neurological illnesses weaken the connections between neurons causing significant altercations in
synaptic plasticity. Synaptic plasticity alterations during HIV infection and recreational drug abuse are mediated by
complex cellular phenomena involving changes in gene expression and subsequent loss of dendritic and spine
morphology and physiology. New treatment strategies with ability to deliver drugs across blood-brain barrier (BBB)
are being intensively investigated. In this context, magnetic nanoparticles (MNPs) based nanoformulations have
shown significant potential for target specificity, drug delivery, drug release, and bioavailability of desired amount of
drugs in non-invasive brain targeting. MNPs-based potential therapies to promote neuronal plasticity during HIV
infection and recreational drug abuse are being developed.
Keywords: HIV/AIDS, Morphine, Nicotine, Methamphetamine, Bath salt, Cocaine, HDAC2, BDNF, Neuropathogenesis,
Blood-brain barrier, Synaptic plasticity, Magnetic nanoparticles
Background
HIV mediated neurotoxicity
It was believed that HIV can enter into the brain only in
the final phase of infection when viral load is higher. How-
ever, many studies show higher HIV concentration even
during the initial infection or shortly after seroconversion
[1, 2]. In fact, presence of HIV-proteins, HIV-DNA, and
HIV-particles in the brain along with the CNS intrathecal
production of anti-HIV antibodies are seen during the ini-
tial infection [2, 3]. This substantiates the belief that HIV
may sneak into the brain from the beginning of infection.
Mononuclear phagocytes, i.e. monocytes and blood-borne
macrophages, are the major carriers of HIV into the brain
[4]. HIV-infected monocytes from blood stream migrate
into the brain in response to specific cytokines/chemo-
kines (e.g. monocyte chemotactic protein-1) [5]. Initial in-
fection of HIV in the brain triggers production of factors
that alter the integrity of the blood brain barrier (BBB)
(e.g. matrix metalloproteinase) and influence leukocytes
transmigration across this barrier [6]. These intensify the
HIV infection in various brain cells. Also, differentiation
of HIV-infected monocytes into macrophages elicits
neuroinflammation by activating astrocytes and resting
microglia [7]. Infection and/or immune activation of mac-
rophages and microglia release neuron-damaging prod-
ucts such as TNF-α, IL-1β, reactive oxygen species, nitric
oxide, and quinolinic acid, [8, 9]. Additionally four viral
proteins, gp120, Tat, Nef, and Vpr have been shown to
induce significant neurotoxicity and associated pathology
[10]. These HIV proteins can be toxic across various
brains cells including neurons (Fig. 1a-b) [11]. The HIV
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envelope protein gp120/gp41 incites activation of chemo-
kine receptors (CXCR4 or CCR5) on neurons and triggers
elevation of intracellular Ca2+ leading to apoptosis [12].
Similarly, gp120 activates NMDA receptors in neurons
and downregulates glutamate uptake by astrocytes causing
excitotoxicity [13]. HIV gp120 also induces nitric oxide
synthase production by astrocytes causing cell death [14].
In macrophages and microglia, gp120 induces production
of proinflammatory factors such as TNF-α, IL-1β, arachi-
donic acid, β-chemokines, etc. [15, 16]. Interestingly,
gp120 also induces apoptosis in brain microvascular endo-
thelial cells (BMVECs) [17] and inhibits proliferation and
migration of neural progenitor cells (NPCs) [18]. Activa-
tion of apoptotic p53 pathway by gp120/gp41 has been re-
ported in neurons, astrocytes, and macrophages/microglia
[19, 20]. The HIV Tat protein induces multiple effects on
neurons: it promotes insertion of NMDA receptors [21],
activates NO and calcium release [22], inhibits tyrosine
hydroxylase [23], and decreases dopamine [24] which
eventually leads to cell death by apoptosis or other
cytotoxicity means. In astrocytes, Tat causes upregulation
of MCP-1 [24] and diminishes glutamate uptake [25].
Similar to gp120/gp41, Tat in macrophages and microglia
induces production of proinflammatory factors such as
TNF-α and IP-10 [26]. HIV Tat exposure in BMVECs
causes apoptosis induction [27] and in NPCs, neurogen-
esis is inhibited due to Tat [28]. The HIV Vpr protein in-
duces apoptosis in different brain cells such as neurons
[29, 30], astrocytes, and BMVECs [31]. In neurons, Vpr
also modulates ion channels [32] and H2O2 upregulation
[33]. Exposure of Vpr to NPCs causes impaired matur-
ation of neurons and mitochondrial dysfunction [34]. The
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In vitro Blood-Brain Barrier Model
 Magnetoliposomes Magnetic layer-by-layer assembly
h    Mechanism of MNPs targeting 
in mouse brain.
i   Proposed schematic of MNPs-based
drugs delivery in human brain
Fig. 1 a–d- Confocal microscopy image showing changes in dendritic and spinal morphology of uninfected/untreated (a), HIV infected (b) [64],
Morphine (c) [76], and Nicotine treated (d) [62] neuroblastoma (SKNMC) cells; e-f- Types of magnetic nanoformulations: Magnetoliposomes
(e) [11] and Magnetic layer-by-layer assembly (f) [72]; g- In vitro BBB model for : Astrocytes-Endothelial cells co-culture in vitro BBB model: Culture
plate is bi-compartmentalized via a transwell porous membrane. The top and underside of this membrane is cultured respectively with tightly
junctioned endothelial cells and astrocytes which correspondingly mimics the external (peripheral blood side) and internal (brain microenvironment side)
surface of BBB. Magnetic force is applied at the bottom of transwell which influence the transmigration of magnetic nanoformulations [11] (h)- Mechanism
of MNPs targeting in rodent model: Anesthetized mouse can be placed in a platform with their head positioned between the poles of magnetic coil and
retained in the desired field for desired time period. i- Proposed schematic of MNPs-based drugs delivery in human brain: Under the influence of in
silico-controlled, non-invasive magnetic force from exterior, drug loaded magnetic nanocarriers can be directly transported across the BBB. Drug release
at target is mediated by manually uncontrollable, cellular responses such as change in temperature, pH, intracellular Ca2
+ level, etc. or by externally
controlled mechanism such as magneto-electric force, radio-frequency magnetic force, etc. Leftover MNPs biodegrades automatically in 2–3 weeks
without negative physiological implications in brain or may be cleared immediately by applying reverse magnetic force
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HIV Nef also induces apoptosis in neurons, astrocytes
[35], and BMVECs [36]. Additionally, Nef modulates [K+]
channels in neurons [37] and induces production of proin-
flammatory factors such as TNF-α, IL-6, MIP-1, and
superoxide release in macrophages and microglia [38]. In
astrocytes, Nef has been also shown to upregulate com-
plement factor C3, MCP-1, IP-10, and MMP-9 activity.
Thus, injury of brain cells by HIV and its proteins involve
various cell-specific mechanisms [39].
Role of drugs of abuse in HIV induced neurotoxicity
Similar to HIV neurotoxicity, recreational drugs alter
brain hemostasis and subsequently damage the CNS.
Neurotoxicity produced by recreational drugs is analo-
gous to HIV infections and many of them have been
shown to promote HIV infections and associated neuro-
pathogenesis (Fig. 1c-d). In fact, it has been shown that
HIV proteins and drugs of abuse can exert additive neuro-
toxic effects. All kinds of recreational drugs including
cannabinoids, methamphetamine, cocaine, opioids, etc.
have been shown to positively regulate HIV-associated
neuropathogenesis [40–45]. Cocaine promotes HIV in-
fectivity in multiple ways with its prime effect on CCR5
upregulation [46]. In synergy with HIV Tat and gp120, co-
caine exacerbates neuronal apoptosis via ROS production
and subsequent activation of the caspase-3 and NFkB
pathway [47, 48]. Also, cocaine disrupts BBB permeability
which causes influx of HIV infected mononuclear phago-
cytes into brain [49]. Methamphetamine is another major
comorbid factor in HIV-induced neuropathogenesis. It
has been shown that methamphetamine and HIV
exert an adverse-additive effect on neuronal and glial
markers and exacerbate the neurocognitive impairments
in methamphetamine-abusing HIV patients. Metham-
phetamine disrupts dopamine levels resulting in oxidative
damage of neurons and has damaging effects on mito-
chondria of astrocytes [50]. The immunomodulatory ef-
fects of opioids have been shown on several hematopoietic
cell populations. Opioids induce the expression of μ and
other chemokine receptors in monocytic cells resulting in
increased HIV susceptibility and stimulation of HIV ex-
pression [51]. Also, opiates enhance the production of
proinflammatory factors like MCP-1, RANTES, IL-6 and
ROS in brain cells [52]. These exacerbate the preexisting
inflammation of neurons due to HIV infections. Addition-
ally, changes in the level of endogenous opioids causes
disruption of dopaminergic functions which affect the
neuro-immunological ability of nervous system to respond
against HIV [53]. Cannabinoids uptake significantly sup-
presses the functional activities of immune cells via activa-
tion of cannabinoids receptors, primarily CB2. Various
studies suggest a link between cannabinoid-mediated
immune suppression and greater susceptibility of HIV in-
fection. As such, it has been proposed that CB2-specific
agonists may be useful agents against neuroinflammation
[54]. Similarly, alcohol exposure alters the BBB, which
lead to increased HIV entry and ROS level in the brain
via influx of macrophages [55]. Thus, recreational drugs
combined with the virus infection results a unique level
of immune incompetence.
Synaptic plasticity dysregulation and magnetic
nanoparticle based therapeutic approach during
neuroAIDS
Synaptic plasticity. Changes during neuroAIDS and drug
abuse
Neuronal synaptic plasticity in this context refers to any
injury-stimulated changes in neuronal processes such as
spine formation, dendritic spines, and synaptic network
reorganization. It has been suggested that HAND symp-
toms in HIV patients are primarily caused by synapto-
dendritic injury [56, 57]. As such, subjects with HAND
exhibit decreased synaptic and dendritic density, result-
ing from apoptosis and atrophy of grey and white
matters [58]. Dendritic spines are postsynaptic speciali-
zations which play a critical role in neuronal plasticity. A
recent study by Atluri et al. [59] showed significant loss
of spines, spine density, dendrite diameter, total den-
drite, and spine area in neuroblastoma cells infected
with HIV-1 clade B and clade C infected. Inter-clade
variations in the density and morphology of spines and
dendrites were also noted [59]. Cells infected with
HIV1-clade B resulted in a 2–2.5 fold decrease in den-
drite diameter, total dendritic area, and spine density.
Similarly, a nearly fivefold decrease in the spine length
and spine area was found in clade B infected cells com-
pared to uninfected cells. The HIV clade C was found to
be less injurious to spine and dendritic phenotypes than
Clade B; nonetheless injury was marked when Clade C
was compared to uninfected cell culture. This inter-
clade variation can be attributed to differences in the
potency of neurotoxic peptides of clade B and clade C.
As an example, Samikkannu et al. [60] reported that Tat
peptide of HIV-1 clade B and C exert different effects on
morphology and spine density, with clade C Tat being
less potent.
One of the major phenotypic consequences of synaptic
plasticity dysregulation is loss of memory. Immediate
events recalled via short term memories are consolidated
into long term memory for later recall by the brain.
Memory consolidation is equally dependent on the
changes in physical appearance of neuronal synapses
and associated gene expression changes. Immediate-
early genes (IEGs), long-term potentiation (LTP) genes,
and long-term depression (LTD) genes are three major
groups of genes playing central role in synaptic plasticity
regulations [59]. It is believed that IEGs mediate LTP to
enhance synaptic strength and consolidate memories.
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Gene expression changes associated with LTD regulate
changes in the neuronal synapse that recycle receptors
and either enhance or inhibit synaptic connections
[61]. Changes in these genes either enhance or depress the
synaptic strength causing synapse remodeling. Atluri et al.
[62] reported that HIV clade B infection of neuroblastoma
cells result in downregulation of 28 major synaptic
plasticity genes (ADCY1, ADCY8, BDNF, CAMK2A,
CDH2, CNR1, CREM, EGR4, GABRA5, GRIA1, GRIN2A,
GRIN2B, GRM1, GRM3, GRM4, GRM7, NCAM1,
NFKB1, NOS1, NTF3, NTRK2, PPP1R14A, PRKCG,
PRKG1, RELN, RHEB, TIMP1, and TNF), while 8 genes
were upregulated (RAB3A, PPP2CA, PIM1, NFKBIB,
IGF1, GRM5, GRIN1, and GRIA4). Treatment of neuro-
blastoma cells by HIV Tat resulted in similar results;
nonetheless upregulated or downregulated gene sets in
this case were different in comparison to HIV infection
[60]. This may be due to differences in neurotoxic potency
of HIV particles and individual HIV neurotoxic peptides.
Similarly, HIV infection to astrocytes resulted in upregula-
tion of 5 genes (EGR2, EGR4, HOMER1, INHBA, and
SYNPO) and downregulation of 28 genes (ADAM10,
AKT1, ARC, CAMK2A, CDH2, CEBPB, CEBPD, CNR1,
CREB1, DLG4, EGR1, FOS, GABRA5, GRIA1, NMDAR1,
GRIN28, GRM1, GRM8, JUN1, JUNB, MAPK1, NFKBIB,
NGFR, NPTX2, PICK1, PLCG1, PPP1CA, PRKCA, RELA,
SIRT1, and SRF) [59]. Cell based variation in the expres-
sion of synaptic plasticity genes during HIV infection may
reflect infectivity intensity where one cell type establishes
latent HIV infection while other is suitable for active
infection. Furthermore, as discussed above, addiction of
recreational drugs is the major complicating factor for
neuroAIDS. Approximately, it is estimated that 13.1 % of
the total number of people who inject drugs are living
with HIV [63]. Various studies suggest that recreational
drugs potentiate the effects of HIV infection in reducing
the neuronal plasticity. For example, treatment of nicotine
during HIV infection in neuronal cells resulted in down-
regulation of 47 genes following a combined treatment of
nicotine and HIV (compared to 23 genes following HIV
alone). Also, spine density was reduced during co-
treatment of nicotine with HIV infection [62]. Similarly,
Sagar et al. [64] showed significant reduction in spine
density following exposure to morphine in the pres-
ence or absence of HIV infection. Methamphetamine
co-treatment of neuronal cells during HIV infection
resulted in additive downregulation of at least 19 genes
and lower spine density [65]. A negative effect of methyle-
nedioxypyrovalerone, the main component of bath salt, a
synthetic recreational drug, has also been reported
where several genes including JUN, JUNB, FOS, RAB3A,
PPP1CA, etc. are significantly dysregulated following
its acute and chronic treatment. Significant reduction
in the spine length, numbers, density, and dendrite
diameters of SKNMC cells were also seen after
methylenedioxypyrovalerone treatment [66]. The effect
of other recreational drugs such as cocaine, alcohol,
etc. on synaptic plasticity genes at cellular level has
been little studied, nonetheless, brain tissue atrophy and
a reduction in neurocognitive performance has been
reported in some studies [58].
Magnetic nanoparticle based therapeutic approaches
MNPs have been extensively investigated for target-
specific drug delivery. Nonetheless, MNPs applications
for brain drug delivery have been little explored. MNPs
possess distinct advantage over other counterparts
(Table 1) such as liposomes, micelles and polymeric
nanoparticles in that its inherent superparamagnetism
allows control over magnetization and therefore the
movement and speed of MNPs can be regulated by an
external magnetic field. Thus, magnetic nanoparticle
based therapeutical formulations can be distributed to
specific body locations by applying non-invasive mag-
netic force (Fig. 1g-i). Importantly, techniques such as
magnetic resonance imaging can be used for quantifying
localized MNPs-associated drugs which may help in
determining site-specific optimal or suboptimal dosing.
Another important facet of MNPs which makes it suit-
able for brain targeting is the flexibility in size. Super
paramagnetic iron oxide nanoparticles of ≤10 nm can be
synthesized which can cross the BBB without affecting
its integrity [67]. In the same line, the basement mem-
brane protein mesh at the BBB has been shown to allow
diffusion of targeted immunoglobulins via transcellular
transport. Moreover, MNPs can be hybridized with lipo-
somes to get “magnetoliposomes” (Fig. 1e). The magne-
toliposomes protect encapsulated drugs loaded on
MNPs from biological degradation, reduce the clearance
and entrapment of nanocarriers by the reticuloendothelial
system, and increase drug bioavailability. Magnetolipo-
somes can also be utilized for the monocytes/ma-
crophage-based nanodrug delivery at inflammatory sites
including the brain [68]. Recently, we have shown the suc-
cessful delivery of magneto electric nano carrier (MENC)
across the BBB into the mouse brain model without
significant toxicity [69].
A variety of biomolecules such as proteins, enzymes,
and synthetic drugs can be immobilized on the exterior
of coated or uncoated MNPs and can be guided magnet-
ically to targeted sites [70]. However, the application of
MNPs for treatment of drug abuse and neuroAIDS is
limited. In recent years, our laboratory has intensively
studied the transendothelial delivery of MNPs-bound
anti-retroviral (ARV) and anti-addiction drugs. ARV
drugs such as 3′-azido-3′ -deoxythymidine-5′ -triphosphate
(AZTTP) and anti-morphine drugs such as CTOP could
be directly (with no additional coatings) immobilized on
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the MNPs surface. It was found that the efficiency of
AZTTP-magnetic nanoformulations, as determined by
suppression of HIV replication, remains comparable to the
free drug. The AZTTP-magnetic nanoformulations were
also hybridized with liposomes which could sustainably re-
lease the drugs for 14 days with intact potency in inhibit-
ing HIV replication [68]. Importantly, under the influence
of an external magnetic field, both AZTTP-magnetic and
AZTTP-magnetoliposome nanoformulations could have
significantly higher (nearly 3 fold) transmigration across in
vitro BBB, compared to free AZTTP, without affecting the
integrity of the BBB. A similar result was obtained with
AZTTP immobilized on magneto-electric nanoparticles
(MENPs), when p24 inhibition efficiency of free drugs was
compared to a.c. triggered released drugs from MENPs
[71]. The sustained release nanoformulations developed
by Jayant et al. [72] was effective in loading 2.8 times
more Tenofovir and it increased the drug release
period by 30-fold. This layer-by-layer nanoformulation
of dextran sulphate bilayer on MNP, sandwiching anti-
HIV drugs in between, showed better blood–brain barrier
transmigration ability (37.95 % ± 1.5 %) and in vitro anti-
viral efficacy (~33 % reduction of p24 level) over a period
of 5 days after HIV infection in primary human astrocytes.
Fiandra et al. [73] showed that PMA coated ultra-small
MNPs (10 nm) improve the permeation of Enfuvirtide
across both in-vitro BBB and mouse models. Wen et al.
[74] explored the transendothelial migration potential of a
magnetoliposome nanoformulation with or without Tat
coating. A dose and time dependent increase in the accu-
mulation of Tat-coated magnetoliposome was seen in the
endothelial cells. It was found that Tat-conjugated magne-
toliposome may be an effective brain drug delivery system
[74]. Raymond et al. [75] explored MNP based targeting
to block the release of Nef containing exosomes from
microglia in in vitro system. This approach showed a posi-
tive impact in protecting in vitro BBB integrity and per-
meability from Nef-exosome toxicity and we speculate
that this technique may be beneficial in preventing or
reducing HIV-associated neuropathogenesis [75]. All of
Table 1 A comparison of various nanoparticle systems: all of these systems are in preclinical stages for targeted delivery of anti-retroviral
and/or anti-addiction drugs to the drug-impenetrable physiological barrier and more rigorous research-homework (particularly in vivo)
has to be elucidated to sort out various associated shortcomings
Nanocarriers Current research standings Technical limitations and potential improvements
Dendrimers ✓ Preclinical: in vitro BBB model shows increased
transmigration of therapeutics; however, yet to be
supported by in vivo transendothelial migration assay.
✓ Synthesis process is complex and drug release is inconsistent or
premature as well.
✓ Polycationic moieties of dendrimers induce cytotoxicity and as such,
its toxicity on various brain cells must be well defined.
Polymers ✓ Preclinical: In vitro and mouse model studies shows
increased transendothelial migration of therapeutics.
✓ Induces transient inflammation and found less ideal for delivery
of polar/ionic compounds. As such occurrences of adverse
effect, if any, on neuronal cells must be defined and potential
of natural polymers should also be explored.
Liposomes ✓ Preclinical: In vitro and rat model studies shows increased
migration of therapeutics across BBB.
✓ Drug entrapment ability, in general, is low and it worsens for the
water-soluble drugs. Further, drug leaching and carrier instability
during storage is also a concern.
✓ Surface modifications such as PEGylation improves the inherent
poor stability of conventional liposomes and can also reduce
their uptake by reticuloendothelial system resulting in improved
bioavailability. Further, it can be developed as “Trojan nanocarrier”
residing in the monocytes/macrophages which naturally
transmigrate across BBB.
Solid-lipid ✓ Preclinical: in vitro BBB model shows increased
trans-endothelia migration of therapeutics.
✓ Although natural ability of lipophilic material (building block of
Solid-lipid nanoparticles (SLN)) to cross the BBB makes SLN a
favorable carrier for brain drug delivery, in vivo trans-endothelial
migration studies are required to authenticate its applicability.
Micelle ✓ Preclinical: In vitro and mouse model studies shows
increased migration of therapeutics across BBB.
✓ Intrinsic nature of particles instability cause premature drug
release. In this regard, neuronal cells specific ligand tethering on
surface of nanocarrier may improve the active brain targeting.
Magnetic ✓ Preclinical: in vitro BBB model shows increased
trans-endothelial migration of therapeutics and several
in vivo study show successful brain delivery of MNPs.
✓ Limited in vivo study showing site-specific targeting and lab-to-land
transfer ability for anti-retroviral and anti-addiction drugs.
✓ Advantages over other nanoparticles: Movement and
speed of nanocarrier can be controlled by external
magnetic force which helps in escape of nanocarriers’
uptake from reticuloendothelial system and subsequently
accelerated active targeting and increased bioavailability
is achieved.
✓ Also, MNPs can be hybridized with liposomes as “Magneto-liposomes”
for development of magnetized “Trojan nanocarrier” residing in the
monocytes/macrophages. While monocytes/macrophages can
naturally transmigrate across BBB, presence of “magneto-liposomes”
in its cytoplasmic space can add to its movement influenced by
external magnetic force.
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these anti-retroviral nanoformulations show great promise
in reducing or eliminating HIV load from the brain. As
such magnetic nanoformulations of other ARV drugs can
be developed. Nonetheless, ARV alone can only prevent
the expansion of HIV mediated damage and may not be
sufficient to revive or promote already damaged neuronal
plasticity during HIV infection. Additionally, synaptic
plasticity dysregulation by illicit drugs is accelerated
during HIV infection and vice-versa (see above). Thus, an
ideal therapeutic approach for treatment of synaptic plas-
ticity dysregulation during neuroAIDS should also be able
to revive and promote neuronal plasticity even when illicit
drugs are present [58]. In this context, a magnetic nano-
formulation of morphine antagonist (CTOP) has been
developed by our group. Confocal microscopy study
revealed that the efficacy of CTOP-magnetic nanofor-
mulations was comparable to free CTOP in protecting
modulation of neuronal dendrite and spine morphology
during morphine exposure and morphine-treated HIV
infection [64]. Similarly, Pilakka-Kanthikeel et al. [76]
investigated a magnetic nanoformulation of a major
neuron-resuscitating agent, BDNF. The BDNF-magnetic
nanoformulation was able to revive the morphine induced
degradation of spine density. Since HIV infection also re-
duces BDNF expression, BDNF-magnetic nanoformula-
tions could be a common therapeutical agent for both
neuroAIDS and drug addiction mediated neuronal plasti-
city dysregulation. In fact experimental evidence support
BDNF as a therapy for HAND. Similarly magnetic nano-
formulations of other agents, which could be beneficial for
synaptic plasticity during neuroAIDS and drug addiction,
could be developed. For example, studies have shown a
neuroprotective role of platelet-derived growth factor via
the induction of the synaptic plasticity gene Arc. Metha-
nandamide, a synthetic stable analog of the endocannabi-
noid anandamide, has been demonstrated to improve
motor function and downregulates the production of
inflammatory mediators in microglial cells [77]. Similarly,
a role for HDAC2 and miR-485 in regulation of synaptic
plasticity genes in HIV infection has been shown [78].
Additionally, HIV latency breaking agents such as vorino-
stat and bryostatin could be beneficial [62]. Thus, mag-
netic nanoformulations of these agents, either singly or in
combination, could be used to promote synaptic plasticity
during neuroAIDS and drug addiction. The cell viability
of the magnetic nanoformulations mentioned above
has been >95 %, making them potentially promising
therapeutic agents. However, much research is required
before the practical application of this approach in a
clinical setting.
MNPs bioavailability and drug release at target
A major advantage of MNPs mediated drug delivery lies
in the quick delivery and early availability of associated
drugs at the targeted site(s) in comparison with contem-
porary nanocarriers. This is achieved by an externally
applied magnetic force which accelerates MNPs-drug
delivery to the target site. The movement of all MNPs
based nanocarriers such as magnetoliposomes or magne-
tized monocytes/macrophages can be manipulated in the
same way as for naked MNPs. For drug delivery into
brain and exposure of magnetic fields, anaesthetized ani-
mals are generally injected intravenously, and subse-
quently placed on a platform with their head positioned
between the poles of magnetic coil and retained in the
field for the desired time (Fig. 1h-i). Several rodent
models have been developed in recent years to study
neuroAIDS transmission and pathogenesis [79]. Kong
et al. [80] have shown that accumulation of 124 nm MNPs
in mouse brain reaches its peak between 15 min and 2 h
with an external magnetic field intensity of ~1000 Oe.
Notably, MNPs level in brain slowly diminished over
time and vanished in 2–3 weeks without negative
physiological effects [80]. Unlike controlled and tar-
geted delivery of MNPs, release of drugs from MNPs
cannot be controlled manually. Fe3O4/Fe2O3 or its de-
rivatives are the most commonly used MNPs in bio-
medicine. These MNPs have an inverse spinel cubic
crystal lattice where face-centered cubic lattice are occu-
pied by O2− anions and tetrahedral and octahedral sites
are occupied by Fe2+ or Fe3+ anions. Octahedral Fe moi-
eties are primarily involved at environmental interfaces
and in an aqueous medium the OH group of water mo-
lecules cause protonation (Fe-OH+H+ = Fe-OH2
+) and
deportation (Fe-OH= Fe-O− +H+), resulting in positive or
negative charged surface depending on the pH of the solu-
tion [81, 82]. Drug molecules containing opposite charge
moieties can be immobilized on the MNPs surface via
ionic interaction in a pH- dependent manner (Fig. 2a).
Similarly, OH2
+, O− or other moieties on MNPs/drug
molecules are generated due to H2O reactivity. This tun-
ability in the surface charge allows binding of a wide range
of biomolecules to MNPs either via ionic interactions or
via surface coating or tethering agents [83, 84]. It is be-
lieved that manually uncontrollable, cellular factors such
as pathology-specific changes in temperature, pH and
intracellular Ca2
+ level mediate drug release by modulating
the original ionic interactions of MNPs and drug molecules.
Recently we have discovered a novel magneto–electric
nanoparticle for targeted drug delivery and on-demand
drug release where under the influence of an external
AC trigger, the symmetry of ionic bonding (charge distri-
bution) between drug molecules and nanoparticles can be
broken, and thus drug release from particles can be
controlled as and when required [11, 85–87]. Similarly,
silica-coated magnetic nano-capsules allow on-demand
drug release via a remote radio-frequency magnetic field
[80]. MNPs can also be coated with a near-infrared-
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photosensitive hydrogel layer which will allow automated
navigation and targeted delivery via an external, non-
invasive magnetic field and near infrared photo-targeting
for sensing and controlled release of drugs [88]. Fur-
thermore, Jayant et al. reported a layer-by-layer (LbL)
assembly (Fig. 1f ) of dextran sulphate on MNPs for
development of sustained release formulation of anti-
retroviral drugs [72]. Nonetheless, development of
externally controlled drug release mechanisms from
MNPs remains a major concern. It is believed that
the application of an external magnetic field generates
torque in the encapsulated MNPs of magnetoliposomes,
magnetic nano-capsules and layer-by-layer assemblies.
This effect significantly disturbs and distorts the external
geometry of nanocarrier causing increased carrier per-
meability (Fig. 2b-c).
Conclusions
Although, highly Active Antiretroviral Therapy (HAART)
has resulted in a remarkable decline in morbidity and
mortality in AIDS patients, viruses still remain in the
brain sanctuary causing neurotoxicity and subsequent
HIV associated neurocognitive disorders (HAND). Also,
HIV infections potentiate the effects of drugs of abuse
in compromising neuronal plasticity (and vice-versa).
Delivery of therapeutic agents including anti-HIV and
anti-addiction drugs to the brain remains a challenge
due to impenetrability of the tightly-junctioned BBB. In
this context, nanotechnology promises exciting pros-
pects for the development of a novel drug delivery sys-
tem to transport the desired therapeutic levels of drugs
across the BBB. Among existing nano-based drug deliv-
ery methods for brain targeting, only MNPs combine
the advantages of target specificity, drug delivery, drug
release and bioavailability of the desired drug concen-
tration. Several modifications in the MNPs-based drug
carrier have been investigated. While MNPs alone can
be sufficient to deliver drugs at target site, magneto-
electric particles can allow control over drug release as
and when required. Similarly, layer-by-layer sustained
release nanoformulations on MNPs can be beneficial in
reducing the therapeutics program from a daily-basis to
longer intervals. Successful implementation of these
therapeutic approaches in clinical settings may provide
a step forward towards achieving near-normal life
expectancy for HIV and drug addiction patients.
Ethics approval and consent to participate
As this study did not involve any animal or human partici-
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approval is not required.
Fig. 2 a - Schematic illustration showing process of drug loading on MNPs. Interaction between negative charge on MNPs surface and positive
charge on different moieties of drug molecules influence drug binding on MNPs [62]. b-c-Geometry of magnetic-polymer layer-by-layer (b) and
magnetoliposomes (c) assembly under magnetic field: Application of external magnetic field generate torque and magnetic pulse in the encapsulated
MNPs such that external layer of carrier is disturbed and distorted. This results in increased carrier permeability [84, 85]
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